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Maternally administered opiate analgesics may
cause a respiratory depression of the newborn.
Such respiratory depression is often not diagnosed
with purely clinical methods such äs the APGAR
score. However, laboratory and clinical — experi-
mental methods may demonstrate a neonatal
depression more clearly [2,3,13].
It has been well documented that the maximal
effect of meperidine occurs within 30—60 minutes
after administration to the mother but that a
neonatal depression may be recognized äs late
äs 2-4 hours after administration of meperidine
[2,9,12].
Opiate antagonists have frequently been re-
commended for the prophylaxis of postpartum
adaption disturbances caused by Opiates. Basically
two kinds of antagonists exist [9]: Agonist-
antagonists such äs nalorphine and levallorphan on
the one hand and pure antagonists such äs naloxone
on the other hand. Agonist-antagonists may cause
a respiratory depression if they are over-dosed
or if there is no opiate present on the receptor
site. This effect is not present with naloxone. If
naloxone is given to the mother 5—15 minutes
before birth or is injected immediately postpartum
into the umbilical vein, the agent wül prevent a
postpartum neonatal respiratory depression [4, 5,
6, 7, 8, 9, 10, 14], Various doses have been re-
1 Narcan®, Endo-JUb, Inc.
commended for the umbilical vein injection [4,6,
7,8,9,11].
The purpose of this study was to investigate the
influence of various naloxone doses on the post-
partum course of neonatal blood gases and acid-
base Status following injection into the umbilical
vein.
l Experimental design and experimental groups
The study was carried out in two parts. Part I
refers to 40 newborns randomly distributed into
four groups. The newborns of Group I/l were the
controls; they had the usual postpartum care and
did not receive naloxone. N'eonates in Group 1/2
received 0.02 mg/kg naloxone into the umbilical
vein, infants in Group 1/3 received 0.03 mg/kg and
those in Group 1/4 0.04 mg/kg of naloxone.
In Part II there were 30 newborns randomly
distributed into three groups. The infants in Group
II/l received immediately postpartum an umbilical
venous injection of placebo, those in Group II/2
0.04 mg/kg naloxone, and those in Group H/3
0.04 mg naloxone.
Part II of this study was designed äs a double
blind study where examiner and follow-up examiner
were not informed about the agent or the dose.
Placebo and the varying amounts of naloxone
doses were distributed in equal amounts of volume
and thus indistinguishable. The mothers of all new-
borns received at a cervical dilation of 3—4 cm
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0.1 mg/kg of dehydrobenzperidol and 0.4 mg/kg
of meperidine intravenously. The usual clinical
variables and blood gases were recorded 30 minutes
after the administration. When labor pain increased
again, another dose of 0.4 mg/kg of meperidine
was injected intravenously at the mothcr's request.
One, five and ten minutes after birth the Apgar
Status of the newborn, blood gas and acid-base
examinations were performed. Blood gas and
acid-base Status was repeated at 30, 60 and 120
minutes after birth. The blood samples were
obtained from the hyperemized heel. pH, PC02,
base-excess Standard bicarbonate, and P02 were




The maternal age was between 25.5 and 28.2
years, their mean weight was 67.7 to 71.3 kg. The
duration of labor was between 107.8 and 144.8
minutes, and the time between the last meperidine
dose and birth was between 66 and 96.1 minutes.
The intravenous dose of meperidine was 0.42 to
0.53 mg/minute, which corresponds to 0.39 to
0.44mg/kg/hour.
The birth weight of the newborns in Part I of this
study was between 3.255 and 3.550 kg.
At the time of delivery the mean maternal pH
values were between 7.38 and 7.40,PC02 between
29.02 and 34.68, P02 between 85.5 and 90.4 mm
Hg. The mean base-excess values were —5.76 to
-6.17 mval/1.
There were no statistically relevant differences
between the neonatal pH values in all four groups
(Fig. 1). The same was true for the neonatal PCO2
values (Fig. 2).
However, a statistically significant difference was
seen for the ;difference of the PC02 values from
the base line Value at one minute (Δ PC02) 30 and
60 minutes after birth in groups 2 and 4 (0.02 and
0.04 mg/kg). In the two naloxone groups the PCO2
values decreased more markedly when compared
to the control group at 30 and 60 minutes after
birth (Fig. 3).
Neither the absolute nor the difference values to
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Fig. l. pH values after birth in relation to various naloxone
doses.
• · controls
o o 0.02 mg/kg naloxone
χ χ 0.03 mg/kg naloxone
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Fig. 2. PCO^ values in neonatesfollowing various naloxone
doses. See legend for Figure 1.
different between the control group and the
naloxone groups (Fig. 4).
Thus, it was documented that under the conditions
of the experiment (dose of meperidine, interval
between meperidine and birth, etc) there were no
significant differences between the controls and
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Fig. 3. Δ PCO2 (= difference between PCO2 at a particular
point in time and the base line value l minute after birth).
An increase of Δ PC02 indicates an increase of the PCO2
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Fig. 4. PO2 values in neonates in relation tp various
naloxone doses.
experimental groups: however, the decrease in the
PC02 values in naloxone groups 1/2 and 1/4 were
more marked than that in the control group. In
order to verify this effect in a double blind exper-
iment a new control group and a naloxone group
with a dose of 0.04 mg/kg were compared with
each other. Added to this experimental group
were ten newborns who received only 0.04 mg of
naloxone.
2.2 Part II
The age of the mothers in Part II was between 25.7
and 26.6 years, they weighed between 70.1 and
75.6 kg. Dehydrobenzperidol was given in total
doses between 7.0 and 7.6 mg; the todal dose of
meperidine was between 32.4 and 61.5 mg. The
duration of labor was between 81.7 and 186.7
minutes, the administration of meperidine between
0.39 and 0.7 mg/minute or 0.33 to 0.56 mg/kg/
hour respectively. The time between the last dose
of meperidine and birth was 54.5 to 69.7 minutes.
The newborns in Part II of the study weighed
between 3247 and 3338 grams. Maternal pH,
PC02, P02 and base-excess values in all three
study groups of Part II were nearly identical and
there were no statistically significant differences.
The pH values of the newborn were not statistically
different in all three groups (Fig. 5). The same was
true for the absolute PC02 values (Fig. 6). While
the PC02 differences in comparison to the base
line value were higher in both naloxone groups
than the control group, this was statistically signif-
icant only for ten minutes after birth (P < 0.05);
the differences were not significant for the other
intervals (Fig. 7). PO2 and base-excess values did
not differ in either the absolute values or the
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Fig. 5. PO2 values in groups II/1-3
• · controls
o o 0.04 mg/kg naloxone
χ χ 0.04 mg naloxone
Indicated are means and Standard deviation of the mean.
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Fig. 8. Course of PO2 values in groups II/1-3. See legend
forFigureS.
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5 — 1 0 - 3 0 - 60 — 120min
Fig. 7. Course of Δ PCO2 in groups II/1-3. See legend for
Figure 5.
3 Discussion
The efficacy of intravenously administerednaloxone
for the prophylaxis and therapy of opiate-related
neonatal respiratory depression has been demon-
strated by various authors with different methods.
GERHARDT et al [10] demonstrated an increase in
Ventilation following 0.1 mg/kg of narcan. The
investigation of EVANS [7,8] with 40 μg did not
show any significant increase in respiratory fre-
quency and alveolar Ventilation but the PC02
values were markedly lower in the naloxone group
than in the control group. Similar results were
found by WBENDER and ROSEN [14].
In Part I of this study we demonstrated a markedly
lower PC02 30 and 60 minutes after birth in the
two groups (Δ PCO2). The double blind study did
not verify this effect at the same times, but there
was a statistically significant difference five
minutes after the administration of naloxone.
There is no difference in the postpartum PO2 values
between the various groups.
Thus, our results differ from the results of some
authors but concur with the findings of CHANG et
al, CLARK et al and MARTIN et al [4, 5, 11]. The
reason for the different results has to be the dose
of the agent and the different dose of meperidine.
MARTIN [11] used mean meperidine doses of
97.4 mg, but did not record the total dose nor the
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interval between the last dose and delivery. The
study by CLARK [5] mentioned total doses of
Meperidin between 150 and 500 mg distributed over
several sub-doses. ROSEN and EVANS [7, 8, 14]
record the total dose of meperidine administered
and its level in the umbilical vein at the time of
delivery but these authors did not measure capillary
blood gas values and acidbase Status while recording
alveolar PCO2 and CO2 production.
The meperidine doses in our study are relatively
low. According to the „Reisensburg recommend-
ations" [1] intravenous application of low doses
of meperidine establishes a base line sedation and
analgesia; the patients at their request received
additional low doses of analgesics intravenously.
Thus, the results of these various investigations
differ in methodology and the dose of meperidine.
Therefore, the basic Situation of the experiment,
namely, the degree of the postpartum respiratory
depression of the newborn, differ in those studies.
The primary reason for the differences should be
the variously high doses of meperidine and the
varyinglong intervals between last dose of meperidine
and delivery. Possibly the routes of administration-
in tramuscularly vs intravenously-are also important.
Thus, it may be assumed in those studies in which
a marked and statistically significant respiratory
effect was demonstrated, that there was a notable
respiratory depression of the newbom. In the
group responding poorly only a minor degree of
respiratory depression of the newborn may have
been present. Thus, those newborns in which there
was no effect should be classified äs being depressed
not due to opiates.
They demonstrate that naloxone in itself does not
cause respiratory depression even if the agent is
overdosed or there isno meperidine on the receptor
site.
In summary, our study and those, previously
published allow the following conclusions:
1. The use of naloxone in the newborn in the post-
partum periodhas no negative effects (in contrast
to nalorphin and levallorphan)
2. In the presence of respiratory depression there
is a significantly faster CO2 elimination (higher
APC02 values) than without the use of naloxone.
3. An optimal dose has not been established in this
study. While 0.04 mg/kg had a stronger effect in
the first part of the experiment than 0.02 mg
and 0.03 mg/kg, but it was also seen that 0.02
mg/kg was more effective than 0.03 mg/kg.
The second part of the study demonstrated that
the administration of 0.04 mg/kg is äs much or äs
little effective äs is the injection of 0.04 mg äs a
total dose.
For clinical purposes the conclusion may be drawn
that if an opiate-related respiratory depression of
the newborn issuspectedit may be treated without
risk and with a dependable effect by the admini-
stration of naloxone.
Summary
The influence of postpartum injections of various doses of
naloxone on the blood gases and acid base Status of 70
newborns was investigated. In Part I of the experiment
groups of 10 newborns each received 0.02, 0.03, or 0.04
mg/kg naloxone through the umbilical vein immediately
after birth; there was a control group of 10 neonates. Part
II of the experiment comprised three groups of ten new-
borns each received immediately after birth into their
umbilical veins an injection of placebo (group 1), 0.04 mg/
kg naloxone (group 2), or 0.04 mg naloxone (group 3).
The second experiment was conducted äs a double blind
study.
All mothers received during labor 0.1 mg/kg dehydro-
benzperidol and 0.4 mg/kg meperidine intravenously
when the cervical dilatation was 3-4 cm. Additionally,
0.4 mg/kg of meperidine was given again if labor pain
increased.
The mean duration of labor was between 81.7 and 186.7
minutes; the time between the last dose of meperidine
and birth was between 54.4 and 96 minutes. The mean
dose of meperidine was between 0.39 and 0.7 mg/minute
or 0.33 to 0.56 mg/kg hour respectively. The course of
the neonatal pH values PCÜ2 and PÜ2 up to two hours
after birth in the first part of the experiment was not
different. However, the PC(>2, i.e. the difference of the
PCO2 values at the various measuring intervals from the
base line value l minute after birth for groups 2 and 4 was
statistically significantly lower at 30 and 60 minutes than
the control group or group 3.
The experimental design of a double blind study in Part II
of these studies again showed no differences in regard to
pH, PCO2, PO2, or base-excess values. While the PCO2
differences from the base line value were larger than the
control group, this was significant only for ten minutes
after birth.
Thus, the experiments allow the conclusion that the use
of naloxone in the neonate during the postpartum period
has no negative effects. In respiratory depression the CO2
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may be eliminated maikedly faster than without the use
of naloxone. Adequate doses are 0.04 mg äs total dose or
0.01 or 0.02 mg/kg. An opiate-related respiratory depression
of the newbom can be treated without risk and reliably
by the use naloxone äs an antagonist.
Keywords: acid-base Status, analgesia, antagonist, birth, blood gases, dehydrobenzperidol, naloxone, neonate, meperidine,
respiratory depression.
Zusammenfassung:
Klinische Untersuchungen zum Einfluß unterschiedlicher
Naloxon-Dosen auf das Neugeborene p o st partum.
An insgesamt 70 Neugeborenen wurde der Einfluß der
postpartalen Injektion unterschiedlicher Dosen von
Naloxon auf die Blutgase und die Parameter des Säuren-
Basen-Haushaltes untersucht. In Teil I erhielten je 10
Neugeborene 0,02 bzw. 0,03 bzw. 0,04 mg/kg Naloxon
unmittelbar postpartal in die Nabelvene injiziert, 10 Neu-
geborene dienten als Kontrollgruppe. Teil II der Unter-
suchungen bezog sich auf 30 Neugeborene, die wiederum
randomisiert auf 3 Gruppen verteilt waren. Die Neu-
, geborenen der Gruppe l erhielten unmittelbar postpartal
' Placebo in die Nabelvene injiziert, die Neugeborenen der
Gruppe 2 0,04 mg/kg Naloxon und die Neugeborenen der
Gruppe 3 0,04 mg Naloxon. Teil II der Untersuchungen
war als Doppelblindversuch angelegt.
Alle Mütter hatten unter der Geburt initial bei einer
Muttermundsweite von 3-4 cm 0,1 mg/kg Dehydrobenz-
peridol und 0,4 mg/kg Dolantin intravenös injiziert er-
halten. Sobald die Wehenschmerzen wieder zunahmen,
wurden jeweils weitere 0,4 mg/kg Dolantin intravenös
nachinjiziert.
Die Geburtsdauer betrug durchschnittlich zwischen 81,7
und 186,7 min, die Zeit zwischen der letzten Dolantin-
Applikation und der Geburt zwischen 54,4 und 96 min.
Der intravenöse Dolantin-Verbrauch lag im Mittel zwischen
0,39 und 0,7 mg/min bzw. 0,33-0,56 mg/kg/h.
Der bis zu 2 h nach der Geburt verfolgte neonatale pH-
Wertverlauf ließ innerhalb des L Teils der Untersuchungen
keinen statistisch relevanten Unterschied erkennen. Das
gleiche traf auf die PCO2-Werte und die PÜ2-Werte zu.
Wurde jedoch PCO2 - d. h. die Differenz der PCO2-
Werte zu den jeweiligen Meßzeitpunkten gegenüber dem
Ausgangswert l min nach der Geburt — gebildet, so ergab
sich in den Gruppen 2 und 4 (0,02-0,04 mg/kg) ein
statistisch signifikanter Unterschied gegenüber der Kon-
trollgruppe und der Gruppe 3; die PCO2-Werte dieser
beiden Gruppen waren 30 und 60 min nach der Geburt
ausgeprägter abgefallen als die PCCVWerte der übrigen
Gruppen.
Auch unter den Bedingungen des Doppelblindversuches -
Teil Ii der Untersuchungen - zeigten sich im pH-Wert-
verlauf, im Verlauf der PC(>2-, PC>2- und Base-Excess-
Werte keine statistisch relevanten Unterschiede zwischen
den Gruppen. Wenn auch die PCO2-Differenzen wiederum
gegenüber dem Ausgangswert in beiden Naxolon-Gruppen
erheblich größer waren als in der Kontrollgruppe, so ließ
sich doch ein statistisch relevanter Unterschied lediglich
10 min nach der Geburt auf dem 5%-Niveau nachweisen
( PC02).
Damit lassen die durchgeführten Untersuchungen die
Schlußfolgerung zu, daß die Applikation von Naloxon an
das Neugeborene in der postpartalen Phase ohne negative
Auswirkungen ist, daß in Anwesenheit einer Atemde-
pression eine deutlich schnellere CO2-Eliminatk>n zu
erwarten ist als ohne die Applikation von Naloxon und
daß eine adäquate Dosierung bereits mit 0,04 mg als
Gesamtdosis bzw. ca. 0,01-0,02 mg/kg erreicht wird.
Wenn eine opiatbedingte respiratorische Depression des
Neugeborenen vorliegt oder vermutet werden kann, läßt
sich diese ohne Risiko und mit zuverlässigem Effekt
durch Naloxon antagonisieren.
Schlüsselwörter: Antagonisten, Atemdepression, Blutgase, Dehydrobenzperidol, Geburt, Naloxon, Neugeborenes,
Pethidin, Säure-Basen-Status, Schmerzbekämpfung.
Resume:
Etüde clinique sur Pinfluence de doses diverses de
naloxone post partum chez les nouveaux-nes
Une etude a ete faite chez 70 nouveaux-nes choisis au
hasard sur l'influence de l'injection postpartale de doses
diverses de naloxone sur les gaz sanguins et des parametres
de teneur acidobasique. L'analyse a porte en lere partie
sur 4 groupes de 10 nouveaux-nes, les trois premiers ayant
re$u respectivement une injection postpartale immediate
dans la veine ombilicale de 0,02, 0,03 et 0,04 mg/kg de
naloxone et le quatrieme servant de groupe de contröle.
La Ileme partie des analyses a porte, a'titre de test temoin
double sur 30 nouveaux-nes repartis en trois groupes.
Ceux du groupe I ont requ de la meme faqon une injection
de placebo, ceux du groupe II 0,04 mg/kg de naloxone et
ceux du groupe III 0,04 mg de naloxone.
Une injection intraveineuse de 0,1 mg/kg de dehydrobenz-
peridol et de 0,4 mg/kg de dolantine avait ete initialement
administree a toutes les meres lorsque Fouverture de
Tuterus avait atteint 3-4 cm; cette injection avait ete
suivie d'une ou de plusieurs autres de 0,4 mg/kg de
dolantine a la reprise des douleurs.
Les accouchements ont dure en moyenne de 81,7 a 186,7
min., le temps ecoule entre la derniere administration de
dolantine et Faccouchement se situant entre 54,4 et 96
min. La quantite totale moyenne de dolantine injectee a
ete de 0,39 a 0,7 mg/min, ou de 0,33 a 0,56 mg/kg/h.
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En ce qui concerne la premiere partie des analyses, l'obser-
vation des valeurs de pH neonatal ainsi que du PCO2 et du
PO2 durant les deux heures successives a l'accouchement
n'a donne aucun resultat significatif. Par contre, PCO2
- c.ad. Panalyse des differences entre les valeurs de PCO2
5, 10, 30, 60 et 120 min. apres Faccouchement et les
valeurs initiales du PCO2 l min. apres l'accouchement -
a montre un ecart statistiquement important entre les
groupes 2 et 4 d'une part et le groupe de contröle d'autre
part: l'administration de 0,02 et de 0,04 mg/kg de naloxone
a provoque, en effet, 30 et 60 min. apres l'accouchement
une baisse plus rapide et plus forte du PCO2.
De meme, dans le test temoin double - Ileme partie des
analyses — on n'a observe aucune difference importante
entre les valeurs de pH, de PCO2, de PO2 et de BE des
trois groupes.
Et bien que les ecarts du PCO2 releve 5,10, 30, 60 et 120
min. apres l'accouchement et compare aux valeurs d'une
minute aient ete beaucoup plus grands que pour le groupe
de controle, on n'a pu retenir un resultat significatif du
point-de-vue statistique que pour les valeurs enregistrees
10 min. apres l'accouchement.
En conclusion, nouspouvonsresumerlesdonneesobtenues
comme suit:
1. Fadministration de naloxone aux nouveaux-nes apres
l'accouchement n'a produit aucun trouble chez ces
derniers,
2. dans les cas de depression respiratoire foetale et neonatale
causee par les analgesiques narcotiques, Fadministration
de naloxone est susceptible d'accelerer et d'accroitre
Felimination de C02 et de stimuler la respiration, la
dose la plus benefique se situant probabiement entre
0,01-0,02 mg/kg ou 0,04 au total.
Ceci signifie qu'en cas de depression respiratoire neonatale
düe a des analgesiques narcotiques, on peut administrer
du naloxone sans danger et avec succes.
Mots-cles: Analgesie, antagonistes, dehydrobenzperidol, depression respiratoire, gaz sanguins, naissance, naloxone,
nouveau-ne, pethidine, Statut acido-basique.
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